Omega‐3 vs placebo
Loss of patency by 12 months · dialysis vascular access outcomes in AVG patients with ESKD
It is very uncertain whether omega‐3 fatty acids changes loss of patency by 6 months compared with placebo (very low certainty).
2 findings from 1 review
- Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes onlyRR 0.91 [0.36, 2.28]2 studies · 41 participantsVery low
- Omega‐3 fatty acids for dialysis vascular access outcomes in patients with chronic kidney disease 2018 · Cochrane Headline outcomes onlyRR 0.59 [0.27, 1.31]2 studies · 220 participantsVery low